The United Kingdom and the United States have reached a significant commercial pact that will guarantee zero import taxes on British medicine products going into the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has pledged to increase funding on medicines through the National Health Service (NHS). This pledge secures that import taxes on these crucial goods will stay at nothing for a duration of the next three years.
This deal comes after recent threats to hike import taxes on patented drug imports, with figures mentioned as high as one hundred percent.
"This deal with the UK bolsters the international landscape for cutting-edge drugs and establishes long-overdue equity to transatlantic medicine commerce," a release said.
Commercial Importance
Drugs are one of the Britain's biggest goods shipped to the United States, which is by far the largest buyer for major companies like GSK and AstraZeneca.
Export figures reveal that in the year to the end of September, the UK sold medicines worth over eleven billion pounds to the US. This amount represented 17.4% of British export trade in that period.
"This agreement secures work, boosts capital expenditure and facilitates the UK to become a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Detailed UK Commitments
The pact includes several specific commitments from the UK:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it considers new therapies to be too expensive by 25%.
- Boosted Medicine Funding: There is a goal to raise overall NHS spending on treatments from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage manufacturers must return to the NHS to stay within budget will be capped at 15%. Last year, repayments topped 20%.
Broader Context
This agreement takes place against a protracted dispute between the sector and the UK government over drug pricing and approval rates.
The disagreement were heightened by claims that American consumers were charged significantly more for the identical medicines than consumers in the other developed nations.
In recent months, several major manufacturing plans in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been pledged toward American operations.
The Science Minister acknowledged that the NHS had to increase expenditure on medicines, noting that its budget allocation on drugs had shrunk as a share of its resources over the last ten years.
